U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC
For NON-U.S. Media Only
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
EX US & UK. Medical Media Only.
Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog
Boehringer Ingelheim receives EU approval for Metacam® for the relief of pain following dehorning in calves
Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves
For Non-US, Non-UK & Non-Canadian Media Only
